Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO

August 14, 2026 8:21 AM

Stifel analyst Annabel Samimy reiterated a Buy rating and $332.00 price target on Ligand Pharma (NASDAQ: LGND).The analyst commented, "At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found